Prognostic Value of Neutrophil to Lymphocyte Ratio for Predicting 90-Day Poor Outcomes in Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

References

• Halpin DMG, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(1):24–36. doi:10.1164/rccm.202009-3533SO
   PubMed Web of Science ®Google Scholar
• Koch M, Butt T, Guo W, et al. Characteristics and health burden of the undiagnosed population at risk of chronic obstructive pulmonary disease in China. BMC Public Health. 2019;19(1):1727. doi:10.1186/s12889-019-8071-8
   PubMed Web of Science ®Google Scholar
• Hurst JR, Siddiqui MK, Singh B, et al. Review of the Humanistic Burden of COPD. COPD. 2021;16:1303–1314. doi:10.2147/COPD.S296696
   Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520–527. doi:10.1136/thoraxjnl-2019-214484
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD: hot topics on acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165. doi:10.1111/resp.12780
   PubMed Web of Science ®Google Scholar
• Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. COPD. 2017;12:2687–2693. doi:10.2147/COPD.S145253
   Google Scholar
• Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
   PubMed Web of Science ®Google Scholar
• Paone G, Leone V, Conti V, et al. Blood and sputum biomarkers in COPD and asthma: a review. Eur Rev Med Pharmacol Sci. 2016;20(4):698–708
   PubMed Web of Science ®Google Scholar
• Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019;74(5):439–446. doi:10.1136/thoraxjnl-2018-211855
   PubMed Web of Science ®Google Scholar
• Celli BR, Anderson JA, Brook R, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research. 2019;6(1):e000431. doi:10.1136/bmjresp-2019-000431
   PubMed Web of Science ®Google Scholar
• de Torres JP, Pinto-Plata V, Casanova C, et al. C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. Chest. 2008;133(6):1336–1343. doi:10.1378/chest.07-2433
   PubMed Web of Science ®Google Scholar
• Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med. 2009;15(2):120–125. doi:10.1097/MCP.0b013e3283218603
   PubMed Web of Science ®Google Scholar
• Moberg M, Vestbo J, Martinez G, Lange P, Ringbaek T. Prognostic Value of C-Reactive Protein, Leukocytes, and Vitamin D in Severe Chronic Obstructive Pulmonary Disease. Scientific World J. 2014;2014:1–7. doi:10.1155/2014/140736
   Google Scholar
• Lv MY, Qiang LX, Li ZH, Jin SD. The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). J Thorac Dis. 2021;13(1):232–243. doi:10.21037/jtd-20-2178
   PubMed Web of Science ®Google Scholar
• Acartürk Tunçay E, Karakurt Z, Aksoy E, et al. Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker. COPD. 2017;12:3361–3370. doi:10.2147/COPD.S147261
   Google Scholar
• Oh YM, Lee KS, Hong Y, et al. Blood eosinophil count as a prognostic biomarker in COPD. COPD. 2018;13:3589–3596. doi:10.2147/COPD.S179734
   Google Scholar
• El-Gazzar AG, Kamel MH, Elbahnasy OKM, El-Naggar MES. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Expert Rev Respir Med. 2020;14(1):111–116. doi:10.1080/17476348.2019.1675517
   PubMed Web of Science ®Google Scholar
• Luo Z, Zhang W, Chen L, Xu N. Prognostic Value of Neutrophil:lymphocyte and Platelet:lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD. IJGM. 2021;14:2839–2848. doi:10.2147/IJGM.S312045
   PubMed Web of Science ®Google Scholar
• Paliogiannis P, Fois AG, Sotgia S, et al. The neutrophil-to-lymphocyte ratio as a marker of chronic obstructive pulmonary disease and its exacerbations: a systematic review and meta-analysis. Eur J Clin Invest. 2018;48(8):e12984. doi:10.1111/eci.12984
   PubMed Web of Science ®Google Scholar
• Sørensen AK, Holmgaard DB, Mygind LH, Johansen J, Pedersen C. Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality – a cohort study. J Inflamm. 2015;12(1):20. doi:10.1186/s12950-015-0064-5
   Google Scholar
• Günay E, Sarınç Ulaşlı S, Akar O, et al. Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease: a Retrospective Study. Inflammation. 2014;37(2):374–380. doi:10.1007/s10753-013-9749-1
   PubMed Web of Science ®Google Scholar
• Teng F, Ye H, Xue T. Predictive value of neutrophil to lymphocyte ratio in patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2018;13(9):e0204377. doi:10.1371/journal.pone.0204377
   PubMed Web of Science ®Google Scholar
• Wang H, Lv C, Wang S, Ying H, Weng Y, Yu W. NLRP3 Inflammasome Involves in the Acute Exacerbation of Patients with Chronic Obstructive Pulmonary Disease. Inflammation. 2018;41(4):1321–1333. doi:10.1007/s10753-018-0780-0
   PubMed Web of Science ®Google Scholar
• Pascual-González Y, López-Sánchez M, Dorca J, Santos S. Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review. COPD. 2018;13:3651–3662. doi:10.2147/COPD.S178068
   Google Scholar
• Ye Z, Ai X, Liao Z, You C, Cheng Y. The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease. Medicine. 2019;98(28):e16371. doi:10.1097/MD.0000000000016371
   PubMed Web of Science ®Google Scholar
• Ayala A, Herdon C, Lehman D, Ayala C, Chaudry I. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood. 1996;87(10):4261–4275. doi:10.1182/blood.V87.10.4261.bloodjournal87104261
   PubMed Web of Science ®Google Scholar
• Lee HUm SJ, Kim YS, et al. Association of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. PLoS One. 2016;116: e0156511. doi:10.1371/journal.pone.0156511.
   PubMed Web of Science ®Google Scholar
• Rahimirad S, Reza M. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(6):653
   Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741. doi:10.1016/S2213-2600(16)30148-5
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• Mendy A, Forno E, Niyonsenga T, Gasana J. Blood biomarkers as predictors of long-term mortality in COPD. Clin Respir J. 2018;12(5):1891–1899. doi:10.1111/crj.12752
   PubMed Web of Science ®Google Scholar
• Moy ML, Teylan M, Danilack VA, Gagnon DR, Garshick E. An Index of Daily Step Count and Systemic Inflammation Predicts Clinical Outcomes in Chronic Obstructive Pulmonary Disease. Annals ATS. 2014;11(2):149–157. doi:10.1513/AnnalsATS.201307-243OC
   Google Scholar
• Duman D, Aksoy E, Coban Agca M, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. COPD. 2015:2469. doi:10.2147/COPD.S90330
   Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: the Rome Proposal. Am J Respir Crit Care Med. 2021;204(11):1251–1258. doi:10.1164/rccm.202108-1819PP
   PubMed Web of Science ®Google Scholar